Literature DB >> 17335304

Economic evaluation and decision making: reimbursing trastuzumab in early-stage breast cancer.

Steven Simoens1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17335304     DOI： 10.2165/00019053-200725030-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

Review 1.  Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.

Authors:  Martine J Piccart-Gebhart
Journal:  Eur J Cancer       Date:  2006-06-27       Impact factor: 9.162

Review 2.  Use of trastuzumab for the treatment of early stage breast cancer.

Authors:  Sofia Braga; Lissandra dal Lago; Chantal Bernard; Fátima Cardoso; Martine Piccart
Journal:  Expert Rev Anticancer Ther       Date:  2006-08       Impact factor: 4.512

3.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.

Authors:  Heikki Joensuu; Pirkko-Liisa Kellokumpu-Lehtinen; Petri Bono; Tuomo Alanko; Vesa Kataja; Raija Asola; Tapio Utriainen; Riitta Kokko; Akseli Hemminki; Maija Tarkkanen; Taina Turpeenniemi-Hujanen; Sirkku Jyrkkiö; Martti Flander; Leena Helle; Seija Ingalsuo; Kaisu Johansson; Anna-Stina Jääskeläinen; Marjo Pajunen; Mervi Rauhala; Jaana Kaleva-Kerola; Tapio Salminen; Mika Leinonen; Inkeri Elomaa; Jorma Isola
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245
  5 in total
  1 in total

1.  Trastuzumab in early-stage breast cancer: the question of treatment timing.

Authors:  Steven Simoens
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.